AC Immune SA (ACIU)
2.91
+0.05
(+1.75%)
USD |
NASDAQ |
Aug 25, 10:00
AC Immune Profit Margin (Quarterly) : 12.40% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.40% |
| March 31, 2026 | -1.32K% |
| December 31, 2025 | -4.25K% |
| September 30, 2025 | -1.69K% |
| June 30, 2025 | -1.62K% |
| March 31, 2025 | -1.92K% |
| December 31, 2024 | -1.39K% |
| September 30, 2024 | 21.59% |
| June 30, 2024 | -3.31K% |
| March 31, 2024 | |
| December 31, 2023 | -32.05% |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | -1.94M% |
| September 30, 2022 | -343.6% |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 |
| Date | Value |
|---|---|
| December 31, 2020 | -2.07K% |
| September 30, 2020 | -1.69K% |
| June 30, 2020 | -1.45K% |
| March 31, 2020 | -62.61% |
| December 31, 2019 | -2.26K% |
| September 30, 2019 | 54.85% |
| June 30, 2019 | -1.12K% |
| March 31, 2019 | 84.72% |
| December 31, 2018 | -1.05K% |
| September 30, 2018 | -586.4% |
| June 30, 2018 | -549.5% |
| March 31, 2018 | -796.6% |
| December 31, 2017 | 25.36% |
| September 30, 2017 | -818.7% |
| June 30, 2017 | -1.64K% |
| March 31, 2017 | -471.3% |
| December 31, 2016 | -333.4% |
| September 30, 2016 | -682.8% |
| June 30, 2016 | 64.86% |
| March 31, 2016 | -1.27K% |
| December 31, 2015 | -1.46K% |
| September 30, 2015 | 82.46% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 13.90% |
| CRISPR Therapeutics AG | -895.3% |
| Idorsia Ltd. | -202.5% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -87.08% |
| Return on Assets | -26.97% |
| Return on Invested Capital | -79.86% |
| Operating Margin (Quarterly) | 7.26% |
| Return on Net Operating Assets | -69.16% |